Sauder Daniel N, Mamelak Adam J
Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-0900, USA.
J Cutan Med Surg. 2004 Jul-Aug;8(4):205-12. doi: 10.1177/120347540400800401.
Encouraging results from clinical trials suggest that biologic therapies are effective treatments for psoriasis.
The aim of our study was to evaluate the scientific evidence for the efficacy and safety of biologic drugs for psoriasis.
The studies reviewed include data on the biologies alefacept, efalizumab, etanercept, and infliximab. This article reviews all data published in the dermatology literature listed in the MEDLINE database, as well as data presented as abstracts and posters at dermatology society meetings, including the annual meetings of the American Academy of Dermatology.
The majority of the studies used an improvement from baseline of 75% or more in the psoriasis area and severity index (PASI 75) as the primary measure of efficacy.
Overall, biologics represent an important addition to the psoriatic therapies and have a great impact on the disease course and life quality of those afflicted with psoriasis.
临床试验取得的鼓舞人心的结果表明，生物疗法是治疗银屑病的有效方法。
我们研究的目的是评估生物药物治疗银屑病的疗效和安全性的科学证据。
所综述的研究包括阿法赛特、依法利珠单抗、依那西普和英夫利昔单抗等生物制剂的数据。本文回顾了MEDLINE数据库中列出的皮肤病学文献中发表的所有数据，以及在皮肤病学学会会议（包括美国皮肤病学会年会）上作为摘要和海报展示的数据。
大多数研究将银屑病面积和严重程度指数（PASI 75）较基线改善75%或更多作为疗效的主要衡量指标。
总体而言，生物制剂是银屑病治疗的重要补充，对银屑病患者的病程和生活质量有很大影响。
